Healthcare / BiotechnologyNasdaqGS
$3.83
+0.15 (+4.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-90.4M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$624M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-149.8%
↓Gross Margin
N/A
•Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-167.9M · FCF $-132.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Net Income | $-167.9M | $-167.9M | $-115.9M | $-67.7M | $-53.0M | $-46.3M | $-33.3M | $-16.9M | $-12.2M |
| EBITDA | $-164.2M | $-164.2M | $-113.4M | $-66.2M | $-53.0M | — | — | — | — |
| EPS | — | — | -2.34 | -1.65 | -1.81 | -1.80 | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | 0.24 | 0.24 | 0.10 | 0.02 | 0.05 | — | — | — | — |
| Current Ratio | 2.95 | 2.95 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-132.3M | $-132.3M | $-90.4M | $-54.2M | $-48.8M | $-35.3M | $-27.4M | $-16.7M | — |
| Returns | |||||||||
| ROE | -149.8% | -149.8% | -76.1% | -28.7% | -50.7% | -39.2% | -30.4% | -12.2% | 114.1% |
| Valuation | |||||||||
| P/B | 3.43 | 3.43 | 0.78 | 3.87 | 2.46 | — | — | — | — |
| Growth & Yield | |||||||||
| EPS Growth | — | — | -41.8% | 8.8% | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+85.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.34 → n/d
Residual
+85.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.